In this audio interview conducted on May 14, 2024, the editors are joined by Jeanne Marrazzo, director of the National ...

Treatment of acute stroke, before a distinction can be made between ischemic and hemorrhagic types, is challenging. Whether very early blood-pressure control in the ambulance improves outcomes ...

Duration and frequency data are based on an analysis of 50 metropolitan areas in the United States. Years included in the 2020s are 2020 and 2021. Data are from the Environmental Protection Agency.

At this prespecified interim analysis (median follow-up, 25.4 months), the percentage of patients with 18-month event-free survival was 70.2% in the nivolumab group and 50.0% in the chemotherapy ...

Dr. Tristan L. Lim (Medicine): A 73-year-old woman was transferred to this hospital because of worsening rash. The patient had been in her usual state of health until 8 days before the current ...

We randomly assigned, in a 1:1 ratio, patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage to receive andexanet or usual care. The primary ...

Including carbon footprint as an end point in randomized, controlled trials could help clinicians, regulators, and policymakers understand the environmental effects of medical interventions.

VITT antibodies feature an oligoclonal or monoclonal antibody profile with a remarkable degree of clonal identity of the light chains, 3,4 which results in a strikingly similar structure of the ...

A 96-year-old woman presented with a 1-day history of pleuritic chest pain 4 days after a pacemaker was implanted for complete heart block. Electrocardiography showed complete heart block.

In this second episode of a four-part Double Take video miniseries on depression from the New England Journal of Medicine, Drs. Anderson, Teel, and Scott-Vernaglia discuss available treatments for ...

Numerous treatment options are currently available to reduce the risk of recurrence in patients with early-stage resectable non–small-cell lung cancer (NSCLC). These approaches include ...

Neoadjuvant nivolumab plus chemotherapy is standard therapy for resectable non–small-cell lung cancer. Whether the addition of adjuvant nivolumab may improve outcomes is unclear. New research ...